NCT05594602View on ClinicalTrials.gov

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

December 14, 2022

Study Completion Date

December 30, 2022

Conditions
COVID-19
Interventions
DRUG

EDP-235

Subjects will receive EDP-235 on Days 1 and 14

DRUG

EDP-235

Subjects will receive EDP-235 on Days 1 and 23

DRUG

EDP-235

Subjects will receive EDP-235 on Days 1 and 8

DRUG

Itraconazole

Subjects will receive itraconazole QD Days 5-18

DRUG

Carbamazepine

Subjects will receive carbamazepine BID Days 5-23 and Days 24-27

DRUG

Quinidine

Subjects will receive quinidine BID Days 5-12

Trial Locations (1)

66219

ICON, plc., Lenexa

Sponsors
All Listed Sponsors
lead

Enanta Pharmaceuticals, Inc

INDUSTRY

NCT05594602 - Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. | Biotech Hunter | Biotech Hunter